FDA Approves Tumor Identification Test
Posted on: Thursday, 31 July 2008, 12:30 CDT
The U.S. Food and Drug Administration has approved a test that can identify cancer cells contained within a malignant tumor.
The FDA said the Pathwork Tissue of Origin test compares the genetic material of a patient's tumor with genetic information on malignant tumor types stored in a database. It uses a microarray technology to analyze thousands of pieces of genetic material at one time. The test considers 15 common malignant tumor types, including bladder, breast and colorectal tumors.
The clearance of the Pathwork test is another step in the continued integration of molecular-based medicine into standard practice, said Dr. Daniel Schultz, director of the FDA's Center for Devices and Radiological Health. In the past, scientists have classified different types of cancers based on the organs in which the tumors develop.
The FDA said the Pathwork Tissue of Origin test was found to provide a level of accuracy similar to that achieved by expert pathologists using current standards of practice.
PathChip, the gene expression array used in the Pathwork Tissue of Origin test, is custom-designed for Pathwork Diagnostics of Sunnyvale, Calif., by Affymetrix Inc. of Santa Clara, Calif.
Source: United Press International
Related Articles
- Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
- Which Biomarker Tests Has the FDA Specifically Suggested It Will Seek to Regulate? Find Out Inside Report 'Trends in the Commercialization of Biomarkers: Tests and Companies'
- Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
- ArthroCare Receives FDA Clearance to Treat Malignant Lesions in the Spine
- NEWSWEEK: Genetic Testing Transforming Diagnosis and Treatment, Tests For Major Illnesses Like Type 2 Diabetes Could Be Available By 2010: 'We Are on the Leading Edge of a Genuine Revolution,' Says Doctor
- German Researchers Detail Efficacy of AMDL's DR-70 Cancer Test As Tumor Marker for Ovarian Carcinoma
- FDA Warns About Unscreened Human Tissue
- Brain Tumors May Originate with Neural Stem Cells, Researchers Say
- The IL-12R[Beta]2 Gene Functions As a Tumor Suppressor in Human B Cell Malignancies
- FDA Sets New Rules on Tissue Donation
 |
 |
User Comments (0)
RSS Feeds